Ertapenem: Difference between revisions
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Ertapenem''' is a [[carbapenem]] [[antibiotic]] marketed by [[Merck & Co.|Merck]] as | '''Ertapenem''' is a [[carbapenem]] [[antibiotic]] marketed by [[Merck & Co.|Merck]] as INVANZ®. It is structurally very similar to [[meropenem]] in that it possess a 1-β-methyl group. | ||
==Category== | ==Category== | ||
Carbapenem | |||
==US Brand Names== | ==US Brand Names== | ||
| Line 25: | Line 26: | ||
'''| [[Ertapenem labels and packages|Labels and Packages]]''' | '''| [[Ertapenem labels and packages|Labels and Packages]]''' | ||
== Mechanism of action == | ==Mechanism of action== | ||
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to [[penicillin binding proteins]] (PBPs). In [[Escherichia coli]], it has strong affinity toward [[Penicillin binding proteins|PBPs]] 1a, 1b, 2, 3, 4 and 5 with preference for [[Penicillin binding proteins|PBPs]] 2 and 3. | Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to [[penicillin binding proteins]] (PBPs). In [[Escherichia coli]], it has strong affinity toward [[Penicillin binding proteins|PBPs]] 1a, 1b, 2, 3, 4 and 5 with preference for [[Penicillin binding proteins|PBPs]] 2 and 3. | ||
Revision as of 00:19, 26 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ertapenem is a carbapenem antibiotic marketed by Merck as INVANZ®. It is structurally very similar to meropenem in that it possess a 1-β-methyl group.
Category
Carbapenem
US Brand Names
INVANZ®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of action
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3.